Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers

Abstract

Objective. Autoantibodies are important in the diagnosis and classification of systemic lupus erythematosus (SLE), but whether they correlate with changes in disease activity within individual patients is controversial. We assessed the association between changes in SLE global and renal activity and changes in several autoantibodies and cell adhesion molecules in patients with SLE. Methods. Stored sera collected at two or three clinic visits from each of 49 SLE patients (91% female, 59% African-American, 31% Caucasian, 10% other ethnicity, 38% under 30 years, 41% between 30–44 years, and 21% 45–63 years) were analyzed. The visits were chosen to include one visit with proteinuria, and one or two without, for each patient. Global disease activity was measured by the Physician’s Global Assessment (PGA), SELENA-SLEDAI (SLE Disease Activity Index modified to exclude anti-dsDNA and complement) and renal activity assessed by urine protein (by urine dipstick) and Renal Activity Score. Sera were assayed for anti-C1q, anti-chromatin, anti-dsDNA, anti-ribosomal P, monocyte chemotactic protein-1 (MCP-1), vascular cell adhesion molecule (VCAM) intercellular adhesion molecule (ICAM) and complement. The associations between changes in disease activity and changes in biomarker levels were assessed. Results. In terms of global disease activity, anti-C1q had the highest association with the PGA (p = 0.09) and was strongly associated with modified SELENA-SLEDAI (p = 0.009). In terms of renal activity, anti-C1q had the highest association with proteinuria (p = 0.079), and was strongly associated with Renal Activity Score (p = 0.006). Conclusion. Anti-C1q performed the best of the potential biomarkers, being significantly associated with the modified SELENA-SLEDAI and with the Renal Activity Score. This study indicates the potential superior utility of anti-C1q over anti-dsDNA and other measures to track renal activity.

Keywords

anti-C1q lupus nephritis

Get full access to this article

View all access options for this article.

References

Tan

Cohen

Fries

. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

Petri

. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus?. Arthritis Rheum 2005; 52: 4003–4010.

Clarke

Panopalis

Petri

. SLE patients with renal damage incur higher health care costs. Rheumatology (Oxford) 2008; 47: 329–333.

Hahn

Antibodies to

DNA

. N Engl J Med 1998; 338: 1359–1368.

Burlingame

. Recent advances in understanding the clinical utility and underlying cause of antinucleosome (antichromatin) autoantibodies. Clin Appl Immunol Rev 2004; 4: 351–366.

Toubi

Shoenfeld

. Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev 2007; 6: 119–125.

Potlukova

Kralikova

. Complement component C1q and anti-C1q antibodies in theory and in clinical practice. Scand J Immunol 2008; 67: 423–430.

Kallenberg

. Anti-C1q autoantibodies. Autoimmun Rev 2008; 7: 612–615.

Wisnieski

Jones

. IgG autoantibody to the collagen-like region of C1q in hypocomplementemic urticarial vasculitis syndrome, systemic lupus erythematosus, and 6 other musculoskeletal or rheumatic diseases. J Rheumatol 1992; 19: 884–888.

10.

Botto

Dell’Agnola

Bygrave

. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998; 19: 56–59.

11.

Holers

. Anti-C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus. J Clin Invest 2004; 114: 616–619.

12.

Siegert

CEH

Kazatchkine

Sjoholms

Wurzner

Loos

Daha

. Autoantibodies against C1q: View on clinical relevance and pathogenic roles. Clin Exp Immunol 1999; 116: 4–8.

13.

Trendelenburg

Marfurt

Gerber

Tyndall

Schifferli

. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum 1999; 42: 187–188.

14.

Seelen

Trouw

Daha

. Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens 2003; 12: 619–624.

15.

Ravelli

Wisnieski

Ramenghi

Ballardini

Zonta

Martini

. IgG autoantibodies to complement C1q in pediatric-onset systemic lupus erythematosus. Clin Exp Rheumatol 1997; 15: 215–219.

16.

Chen

Wang

Liu

Chen

Liang

. Correlation between the renal C1q deposition and serum anti-C1q antibody: A potential role of anti-C1q antibody in lupus nephritis. Asian Pac J Allergy Immunol 2002; 20: 223–227.

17.

Amoura

Koutouzov

Chabre

Cacoub

Amoura

Musset

. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 76–84.

18.

Cairns

McMillan

Crockard

. Antinucleosome antibodies in the diagnosis of systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 272–273.

19.

Cervera

Vinas

Ramos-Casals

. Anti-chromatin antibodies in systemic lupus erythematosus: A useful marker for lupus nephropathy. Ann Rheum Dis 2003; 62: 431–434.

20.

Springer

. Adhesion receptors of the immune system. Nature 1990; 346: 425–434.

21.

Cronstein

Weissmann

. The adhesion molecules of inflammation. Arthritis Rheum 1993; 36: 147–157.

22.

Golias

Tsoutsi

Matziridis

. Leukocyte and endothelial cell adhesion molecules in inflammation focusing on inflammatory heart disease. In Vivo 2007; 21: 757–769.

23.

Tulek

Aydintug

Ozoran

. Soluble intercellular adhesion molecule-1 (sICAM-1) in patients with systemic lupus erythematosus. Clin Rheumatol 1996; 15: 47–50.

24.

Spronk

Limburg

Kallenberg

CGM

. Review. Serological markers of disease activity in systemic lupus erythematosus. Lupus 1995; 4: 86–94.

25.

Spronk

Ter Borg

Huitema

Limburg

Kallenberg

. Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: A prospective study. Ann Rheum Dis 1994; 53: 235–239.

26.

Mason

Kapahi

Haskard

. Detection of increased levels of circulating intercellular adhesion molecules 1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus. Arthritis Rheum 1993; 36: 519–527.

27.

Grootscholten

Dieker

JWC

McGrath

. A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisone. Ann Rheum Dis 2007; 66: 693–696.

28.

Moroni

Trendelenburg

Del Papa

. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 2001; 37: 490–498.

29.

Bigler

Lopez-Trascasa

Potlukova

. Antinucleosome antibodies as a marker of active proliferative lupus nephritis. Am J Kidney Dis 2008; 51: 624–629.

30.

Magder

Barr

Petri

. Decrease in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2342–2349.

31.

Petri

Kasitanon

Lee

. Systemic Lupus International Collaborating Clinics renal activity/response exercise: Development of a Renal Activity Score and Renal Response Index. Arthritis Rheum 2008; 58: 1784–1788.

32.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

33.

Petri

Kim

Kalunian

. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550–2558.

34.

Petri

Hellmann

Hochberg

. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992; 19: 53–59.

35.

Moura

Lima

Barbosa

. Anti-C1q antibodies: Association with nephritis and disease activity in systemic lupus erythematosus. J Clin Lab Anal 2009; 23: 19–23.

36.

Matrat

Veysseyre-Balter

Trolliet

. Simultaneous detection of anti-C1q and anti-double-stranded DNA autoantibodies in lupus nephritis: Predictive value for renal flares. Lupus 2011; 20: 28–34.

37.

Ter Borg

Horst

Hummel

Limburg

Kallenberg

. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: A long-term, prospective study. Arthritis Rheum 1990; 33: 634–643.

38.

Bootsma

Spronk

Derksen

. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 1595–1599.

39.

Ikeda

Fujimoto

Ameno

Shiiki

Dohi

. Relationship between lupus nephritis activity and the serum level of soluble VCAM-1. Lupus 1998; 7: 347–354.

40.

Siedner

Gelber

Rovin

. Diagnostic accuracy study of urine dipstick in relation to 24-hour measurement as a screening tool for proteinuria in lupus nephritis. J Rheumatol 2008; 35: 84–90.